Skip to main content

ASCPT 2023 Annual Meeting Main banner

Tweets by ASCPT 2023 Annual Meeting

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

A
PI-093
A COMPREHENSIVE MIDD APPROACH TO ASSESS THE SAFETY AND EFFICACY OF TARGETED-THORIUM-CONJUGATES IN PATIENTS FOR EARLY DECISION MAKING.

Favorite
PI-010
A DDI STUDY TO EVALUATE THE EFFECT OF MULTIPLE ORAL ADMINISTRATION OF RIFAMPICIN ON THE PHARMACOKINETICS OF VALEMETOSTAT IN HEALTHY PARTICIPANTS.

Favorite
EP-032
A FIRST-IN-HUMAN PHASE I STUDY OF THE GFH312 A RIPK1 INHIBITOR, EVALUATING SAFETY/TOLERABILITY AND PHARMACOKINETICS IN HEALTHY SUBJECTS.

Favorite
PT-014
A GLOBAL PROTEOMICS ANALYSIS OF THE ONTOGENY OF THE BLOOD-BRAIN BARRIER.

Favorite
PT-006
A LESION-CENTRIC AND TARGET-SPECIFIC PKPD MODEL OF PYRAZINOIC ACID IN PATIENTS WITH TUBERCULOSIS.

Favorite
PWII-002
A MATHEMATICAL MODEL FOR SELECTING REGIMEN COMPOSITION AND DURATION BASED ON PHENOTYPE FOR PATIENTS WITH DRUG-SUSCEPTIBLE TUBERCULOSIS.

Favorite
PII-020
A MATHEMATICAL MODEL FOR SELECTING REGIMEN COMPOSITION AND DURATION BASED ON PHENOTYPE FOR PATIENTS WITH DRUG-SUSCEPTIBLE TUBERCULOSIS.

Favorite
PI-033
A MECHANISTIC PK/PD MODEL OF AZD0171 (ANTI-LIF) TO SUPPORT PHASE 2 DOSE SELECTION.

Favorite
PII-123
A MODEL-BASED META-ANALYSIS TO ASSESS THE SIMILARITIES AND DIFFERENCES OF CLINICAL SAFETY OF TARGETED-THORIUM-CONJUGATES IN PATIENTS.

Favorite
PI-034
A MULTI-PURPOSE FIRST-IN-HUMAN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACT-777991, AN ORAL C-X-C MOTIF CHEMOKINE RECEPTOR 3 (CXCR3) ANTAGONIST.

Favorite
PT-025
A NOVEL REGULATORY VARIANT PROMOTES CYP2D6 ALTERNATIVE SPLICING AND REDUCES FULL-LENGTH CYP2D6 PROTEIN LEVELS IN LIVER SAMPLES.

Favorite
EP-033
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NON-RANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS.

Favorite
LB-003
A PHASE I, RANDOMIZED, OPEN-LABEL, CROSSOVER, FIXED-SEQUENCE STUDY TO EVALUATE THE PK, D0SE-PROPORTIONALITY, BIOAVAILABILITY, AND TOLERABILITY OF SUBCUTANEOUS LEVOTHYROXINE SODIUM (XP-8121) IN HEALTHY ADULT SUBJECTS.

Favorite
PI-074
A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL EVALUATING THE DRUG-DRUG INTERACTION (DDI) POTENTIAL BETWEEN LAMOTRIGINE (LMT) AND ACETAMINOPHEN (APAP).

Favorite
PI-035
A POPULATION PHARMACOKINETIC ANALYSIS OF ESCITALOPRAM AND THE EFFECT OF CYP2C19 ON CLEARANCE IN CHILDREN AND ADOLESCENTS.

Favorite
LB-007
A POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODEL FOR CARFILZOMIB IN COMBINATION WITH IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA.

Favorite
PI-094
A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF SEPSIS-INDUCED AUGMENTED RENAL CLEARANCE.

Favorite
PI-021
A RETROSPECTIVE GENOME-WIDE ASSOCIATION STUDY OF ANTIPSYCHOTIC DRUG RESPONSE IN PEDIATRIC PATIENTS WITH PSYCHIATRIC ILLNESS IN A RURAL HEALTHCARE SETTING.

Favorite
EP-004
A SINGLE CENTRE, PROSPECTIVE STUDY TO EVALUATE THE EFFECT OF DOUBLE CARBAPENEM BASED COLISTIN THERAPY VERSUS BEST AVAILABLE THERAPY FOR THE TREATMENT OF CARBAPENEM RESISTANT ENTEROBACTERIACEAE AT A TERTIARY CARE HOSPITAL IN INDIA.

Favorite
PWII-004
A SURVEY OF REGRESSION ANALYSIS METHODS ADOPTED IN RENAL IMPAIRMENT STUDIES.

Favorite
PII-107
A SURVEY OF REGRESSION ANALYSIS METHODS ADOPTED IN RENAL IMPAIRMENT STUDIES.

Favorite
LB-015
A TRANSLATIONAL COMPUTATIONAL MODEL OF ALLERGEN CHALLENGE TO SUPPORT THE CLINICAL DEVELOPMENT OF AN INTRANASALLY ADMINISTERED BACTERIAL LYSATE IN MILD ASTHMA.

Favorite
PI-036
AN IN SILICO SIMULATION STUDY OF EXTENDED INTERVAL DOSING OF ATEZOLIZUMAB USING POPULATION PHARMACOKINETICS.

Favorite
PII-120
AN INTERIM PHARMACOKINETIC (PK) ANALYSIS OF CANNABINOIDS IN SERUM OF VOLUNTEERS RECEIVING COSMETIC HEMP EXTRACT VIA THE ORAL OR TOPICAL ROUTES.

Favorite
EP-005
AN OPEN-LABEL BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS TO COMPARE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET STRENGTHS OF SOTORASIB.

Favorite
PI-101
AN OPEN-LABEL SINGLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS OF SOTORASIB IN HEALTHY SUBJECTS AND SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.

Favorite
EP-006
AN OPEN-LABEL STUDY TO ASSESS THE EFFECT OF COADMINISTRATION OF SOTORASIB ON THE PHARMACOKINETICS OF ROSUVASTATIN, A BREAST CANCER RESISTANCE PROTEIN SUBSTRATE, IN HEALTHY SUBJECTS.

Favorite
PI-037
AN OPEN-LABEL STUDY TO ASSESS THE EFFECT OF ITRACONAZOLE AND RIFAMPIN ON INCB000928 PHARMACOKINETICS WHEN ADMINISTERED ORALLY IN HEALTHY PARTICIPANTS.

Favorite
PI-022
ANALYSIS OF TICAGRELOR AND PRASUGREL CORRELATION WITH CYP2C19 GENETIC VARIANTS AS ALTERNATIVE DRUGS FOR CLOPIDOGREL.

Favorite
PWI-005
APPLICATION OF A PERMEABILITY-LIMITED MULTI-COMPARTMENT LIVER MODEL TO INVESTIGATE RIFAMPICIN-MEDIATED ZONAL INDUCTION OF HEPATIC OATP1B1 IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) FRAMEWORK.

Favorite
PII-095
APPLICATION OF A PERMEABILITY-LIMITED MULTI-COMPARTMENT LIVER MODEL TO INVESTIGATE RIFAMPICIN-MEDIATED ZONAL INDUCTION OF HEPATIC OATP1B1 IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) FRAMEWORK.

Favorite
PWII-005
APPLICATION OF MACHINE LEARNING (ML) ON QSP VIRTUAL PATIENT POPULATION (VPOP) FOR IDENTIFICATION OF BIOMARKERS OF RESPONSE AND FOR SELECTION OF PRE-CONDITIONING REGIMEN FOR ENGINEERED T-CELL (ET-CELL) THERAPY.

Favorite
PII-124
APPLICATION OF MACHINE LEARNING (ML) ON QSP VIRTUAL PATIENT POPULATION (VPOP) FOR IDENTIFICATION OF BIOMARKERS OF RESPONSE AND FOR SELECTION OF PRE-CONDITIONING REGIMEN FOR ENGINEERED T-CELL (ET-CELL) THERAPY.

Favorite
PI-075
APPLICATION OF MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC/PHARMACODYNAMIC MODEL FOR INSULIN.

Favorite
PI-038
APPLICATION OF MODELING AND SIMULATION TO EXTRAPOLATE THERAPEUTIC BUROSUMAB DOSING REGIMENS FOR SUBJECTS WITH PEDIATRIC TUMOR-INDUCED OSTEOMALCIA.

Favorite
PI-039
APPLICATION OF POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING TO SUPPORT DOSAGE REGIMEN OF FESOTERODINE IN PEDIATRICS WITH NEUROLOGICAL DETRUSOR OVERACTIVITY.

Favorite
PI-040
ASSESSING THE GOLDENSEAL-METFORMIN PHARMACOKINETIC INTERACTION IN TYPE 2 DIABETICS.

Favorite
E-003
ASSESSMENT OF TREATMENT PATHS FOR OUD PATIENTS AFTER AN ACUTE OUD EVENT.

Favorite
PI-001
ASSOCIATION BETWEEN BLEEDING RISK AND INITIAL P2Y12 INHIBITOR SELECTION AND DE-ESCALATION AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) AND PERCUTANEOUS CORONARY INTERVENTION (PCI).

Favorite
RWE-005
ASSOCIATION BETWEEN BLEEDING RISK AND INITIAL P2Y12 INHIBITOR SELECTION AND DE-ESCALATION AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) AND PERCUTANEOUS CORONARY INTERVENTION (PCI).

Favorite
PT-009
ASSOCIATION BETWEEN TACROLIMUS AND CYP3A5 GENOTYPE IN PEDIATRIC KIDNEY TRANSPLANT.

Favorite